GLP-1 analogues in clinical management of obesity

Abstract

Obesity is a chronic disease requiring chronic management. Anti-obesity medication for the treatment of obesity includes the glucagon-like peptide-1 (GLP-1) agonists liraglutide and semaglutide. This review will discuss the results of weight loss clinical trials for these agents, in addition to anorectic gut hormone analogue combinations and co-agonist drugs targeting gut hormone receptors, as well as the implications for the clinical management of obesity.